Day One Biopharmaceuticals, Inc (DAWN)

Day One Biopharmaceuticals, Inc's Q·Score is 4.5/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.0× debt-to-equity). Key area to monitor: currently unprofitable (-68% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for DAWN is $21.50, based on ratings from 6 Wall Street analysts. This is 0.1% below the current price of $21.53. Price targets are forward-looking estimates and not guarantees of future performance.

Day One Biopharmaceuticals, Inc (DAWN) scores below peers on valuation metrics, trading above typical sector multiples.

Day One Biopharmaceuticals, Inc is scheduled to report earnings in 2 days, on May 5, 2026.

Day One Biopharmaceuticals, Inc has a net profit margin of -67.8%, indicating the company is currently operating at a net loss. Its gross margin stands at 89.1%, indicating a high-margin business model.

Day One Biopharmaceuticals, Inc is reporting strong year-over-year growth of 83.9%.

Day One Biopharmaceuticals, Inc has a debt-to-equity ratio of 0.01×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 8.02×, indicating comfortable short-term liquidity.